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the clinical trial and assumed equal in the models. Costs and outcomes beyond 
first year were discounted at a 5% annual rate. RESULTS: Denosumab was 
associated with lower frequency of SRE due to clinical superiority versus ZA, and 
with higher costs. The incremental cost per SRE avoided was estimated at 
$78,844. Although a formal threshold for this outcome is not available in Mexico, 
the ICER obtained is 40% below the commonly accepted threshold in Mexico 
(based on the GDP per capita). The ICER remained below the local accepted 
threshold in all univariate sensitivity analyses. In the probabilistic sensitivity 
analysis, denosumab became the most preferred option from a willingness to 
pay of approximately 100 000 Mexican pesos. CONCLUSIONS: These results 
suggest denosumab represents good value for money in the prevention of SRE in 
prostate cancer patients with BM in Mexico.  
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OBJECTIVES: To evaluate the most cost-effective strategy of staging non-small 
cell lung cancer with hybrid PET/CT to avoid unnecessary surgeries. METHODS: 
A decision tree model was developed with four work-up approaches: CT alone, 
PET/CT for all, PET/CT when negative CT, and CT plus PET/CT for all. 
Mediastinoscopy was included in all alternatives to confirm positive CT or 
PET/CT. Surgery was considered unnecessary when the work-up drives to 
resectable stage but the model predicts loco regional or distant metastasis. The 
model incorporated evidence-based data from the literature and associated costs 
were evaluated from the Brazilian public health care system perspective. The 
costs of PET/CT in Brazil were estimated in previous study by microcosts 
technique. The impact of uncertainties on the model was verified by 
deterministic and probabilistic sensitivity analyses (PSA). RESULTS: For each 
strategy, a simulation of 1000 individuals has shown the costs and effects (US$/ 
avoidable surgery) as follow: US$1.088.248,85/ 0; US$2.620.087,94/ 151; 
US$2.432.104,45/ 170 and US$2.740.718,99/ 181, respectively. The incremental 
cost-effectiveness ratio (ICER) per avoidable surgery was more favorable for 
PET/CT in negative CT (US$7.888/ surgery) than PET/CT for all (US$10.127/ 
surgery) and CT plus PET/CT (US$9.108/ surgery) versusCT alone. In sensitivity 
analysis, estimates of ICER were sensitive to changes in the probability of distant 
metastasis, the cost of PET/CT procedure and probability of N0/1 disease. 
CONCLUSIONS: Although PET/CT is recommended for staging potential 
resectable lung cancer patients, the procedure is not reimbursed in Brazilian 
public health care system yet. Our study shows that include PET/CT in the work-
up staging of lung cancer could prevent misleading surgeries due to undiagnosed 
advanced disease. In term of cost-effectiveness, PET/CT in negative CT patients 
is the most cost-effective strategy with a probability higher than 90% when the 
willingness-to-pay is US$10.000,00 superior.  
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OBJECTIVES: To evaluate the cost-effectiveness of using Oncotype DXTM to 
inform adjuvant chemotherapy treatment decisions versus standard clinical 
practice (use of traditional clinical and pathological criteria). Oncotype DX is a 
21-gene assay that provides an individualized prediction of chemotherapy 
benefit and 10-year distant recurrence for patients with hormone receptor 
positive, human epidermal growth receptor 2 negative (HER2–), early-stage 
breast cancer. METHODS: A Markov model was developed to make long-term 
projections of distant recurrence, survival, and direct costs for patients described 
above. Scenarios using Oncotype DX to inform treatment recommendations for 
adjuvant chemotherapy or conventional procedures were modeled based on 
published decision impact studies. Transition probabilities and risk adjustment 
were based on published landmark trials. Costs are reported in U.S. dollars at an 
exchange rate of 13.17 MXN per dollar (average 2012) and were estimated from 
an Instituto Mexicano del Seguro Social (IMSS) perspective based on published data. 
Future costs and clinical benefits were discounted at 5% annually. Sensitivity 
analyses were performed. RESULTS: 29.5% of early-stage breast cancer patients 
were spared chemotherapy following Oncotype DX testing, whilst 5.6% of 
patients received chemotherapy in addition to hormone therapy. Long-term 
modeling analysis showed that optimized therapy allocation following Oncotype 
DX testing led to an improvement in mean life-expectancy of 0.068 years per 
patient and increased direct costs by $129.6 per patient versus usual care. This 
equated to an incremental cost effectiveness ratio (ICER) of $1,917 per life-year 
gained. In a secondary analysis of patients previously recommended 
chemotherapy, use of Oncotype DX was associated with avoidance of 
chemotherapy in 46% of patients, leading to cost savings of $2,082 per patient, 
with life expectancy maintained at the level expected with standard care. 
CONCLUSIONS: Using Oncotype DX was projected to be cost-effective in 
comparison with the current standard of care.  
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OBJECTIVES: To evaluate the cost-effectiveness of primary and secondary 
prophylaxis (PP and SP) with pegfilgrastim, filgrastim (6-day and 11-day), or no 
prophylaxis for decreasing the incidence of febrile neutropenia (FN) in recurrent 
ovarian cancer patients receiving 3 cycles of myelosuppressive chemotherapy 
(docetaxel every 21 days 100 mg/m2, FN risk ≥20%) over a lifetime horizon from a 
U.S. payer perspective. METHODS: A Markov cycle tree model tracks FN events in 
chemotherapy cycles 1-3 (3-week cycles) and long-term survival (1-year cycles). 
Long-term survival is modeled according to received relative dose intensity (RDI), 
which correlates with FN history. Model inputs, including efficacy (relative risk of 
FN compared to no prophylaxis) of each strategy, effects of FN on RDI, mortality, 
costs, and utilities, were estimated from public sources, research databases, and 
peer-reviewed publications. Expected lifetime costs and quality-adjusted life-
years (QALYs) (discounted 3% per year) were estimated for each strategy. 
Probabilistic sensitivity analyses (PSA) were conducted. RESULTS: The 
incremental cost-effectiveness ratio (ICER) for PP versus SP with pegfilgrastim 
was $15,946 per QALY gained. Total lifetime costs for PP and SP with 
pegfilgrastim were $13,034 and $12,704, respectively, while lifetime QALYs were 
0.916 and 0.895. PP with pegfilgrastim dominated all other comparators. 
Although ICER results of PP versus SP with pegfilgrastim may be affected by 
changes in baseline FN risk, pegfilgrastim efficacy, pegfilgrastim cost, and cost of 
FN-related hospitalization, PP was cost-effective compared to SP in 95% and 
100% of PSA simulations at thresholds of $50,000 and $100,000 per QALY, 
respectively. CONCLUSIONS: From a U.S. payer perspective, PP with 
pegfilgrastim is cost-effective compared to other prophylaxis strategies in 
recurrent ovarian cancer patients receiving docetaxel.  
 
PCN72  
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OBJECTIVES: Prostate cancer is the most common malignancy in the male. It has 
become a major public health problem in the Bahamas particularly among blacks 
and identified as one of the major contributors to mortality. Luteinizing hormone 
releasing hormone (LHRH) agonist monotherapy is the first line treatment in 
cases of metastatic prostate cancer as Bahamian patients generally refuse 
surgical castration. Among the available LHRH agonist, goserelin and luprolide 
are the only two drugs that are available on the Bahamas national drug 
formulary. The objective of this study was to conduct a cost effectiveness 
analysis of goserelin acetate 10.8 mg depot versus leuprolide acetate 7.5 mg 
depot in the treatment of metastatic prostate cancer in the Bahamas, from a 
societal perspective. METHODS: Cost and probabilities of outcomes were derived 
from the hospital data and published literature. Direct & indirect costs included 
were physician and nursing cost, drug cost, diagnostic and lab costs; loss of 
wages and cost of travel. Primary outcomes were month of life gained and 
adverse events. A one way sensitivity analyses were conducted by varying the 
cost and survival by 25%. Hospital data on survival was reviewed for 2 years from 
the initiation of treatment. RESULTS: The cost effectiveness analysis showed 
that the leuprolide was the least costly alternative to goserelin (US$6268 vs. 
$7156 per patient). The incremental cost effectiveness ratio (ICER) of leuprolide 
compared to goserelin was $286 per month of life gained. Results were sensitive 
to variations in costs and month of life gained by 25% proving leuprolide being a 
dominant option over goserelin. Leuprolide was found being less expensive both 
to the patient as well as to the payer. CONCLUSIONS: Lueprolide appears to be 
the least costly approach for the treatment of metastatic prostate cancer in the 
Bahamas, from a societal perspective. Further investigations are needed to 
confirm its cost effectiveness considering other cost variables & quality of life.  
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University of Houston, Houston, TX, USA  
OBJECTIVES: Tamoxifen and raloxifene has been approved by US FDA for breast 
cancer chemoprevention. Exemestane was also found to have promising effects 
on breast cancer prevention based on 3 years follow-up of MAP.3 trial. The 
objective of the study was to assess the cost-effectiveness of continuing therapy 
with tamoxifen for 5 years versus switching to exemestane or raloxifene, after 2 
years of treatment with tamoxifen in postmenopausal women in the United 
States from third party payer perspective. METHODS: A Markov model was 
developed using Treeage pro suite 2009, where cost and health outcomes were 
utilized for estimating quality adjusted life year (QALY). A hypothetical cohort of 
1000 women with 5 year predicted breast cancer risk (≥ 1.66) based on the Gail et 
al. model, history of lobular carcinoma in-situ, and history of atypical 
hyperplasia was simulated using the Markov model. The model was developed 
comprising of 5 health states (Healthy, Adverse Event, Breast Cancer, Death  
due to Breast Cancer, and Death due to Other Causes) to calculate incremental 
costs per QALY gains for tamoxifen, raloxifene and exemestane. Annual 
transition probabilities were derived from NSABP P-1 and NSABP P-2 trials (for 
tamoxifen and raloxifene) and MAP.3 trial (for exemestane). Direct costs and 
utilities were literature-based. Costs and benefits were discounted at 3% 
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annually. Two-way sensitivity analyses were performed by varying values for 
key parameters in the model. RESULTS: Under base-case scenario, gain of QALYs 
per patient associated with exemestane (29 QALYS) was higher compared with 
tamoxifen (28 QALYS) and raloxifene (28 QALYS). The cost of gaining one QALY 
with exemestane ($44,723) was found to be low compared to tamoxifen ($93,053) 
and raloxifene ($70,940). These results were robust to the two-way sensitivity 
analyses performed. CONCLUSIONS: Results suggested that switching to 
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OBJECTIVE: Colorectal cancer (CRC) is one of the leading causes of cancer-related 
deaths in Australia and a common cause of morbidity and mortality worldwide. 
Screening is an attractive option since there is an identifiable precursor lesion 
and the bowel is readily accessible for screening. In addition, the early detecting 
of CRC or adenoma has been proven to reduce CRC-associated mortality. The 
faecal-occult blood test (FOBT) is a widely-used cost-effective screening tool for 
large-scale bowel cancer screening programs. In 2006, a National Bowel Cancer 
Screening Program (NBCSP) was established in Australia, using an 
immunochemistry-based FOBT. The Program currently targets all Australians 
who turn 50, 55 or 65 years of age between January 2011 and December 2014. 
Despite the proven impact of screening on reducing bowel cancer mortality, the 
uptake of the NBCSP has been low. OBJECTIVES: To evaluate the cost-
effectiveness of a patient-direct mailed advance notification letter, on 
participants of the NBCSP in Australia. METHODS: This study followed a 
hypothetical cohort of 50-year-old, 55-year-old and 65-year-old patients 
undergoing FOBT screening through a Decision analytic Markov model. The 
intervention compared two strategies: 1) Advance letter, NBCSP and FOBT 
compared with 2) NBCSP and FOBT. The main outcome measures were life years 
gained (LYG), quality-adjusted life years (QALY) gained and incremental cost-
effectiveness ratio (ICER). RESULTS: An advance notification screening letter 
would yield an additional 54 per 100,000 CRC deaths avoided compared with no 
letter. The estimated cost-effectiveness was $3976 per LYG and $6976 per QALY 
gained. CONCLUSIONS: An advance notification letter in the NBCSP may have a 
significant impact on life years gained and cancer deaths avoided. It is cost-
effective and offers a feasible strategy that could be rolled out across other 
screening program at an acceptable cost.  
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OBJECTIVES: The escalating cost of innovative new cancer therapies has 
received increased attention in the medical literature and popular press. Cost-
utility analyses (CUAs) provide information on value for money and are widely 
published in medical and economic literature. We describe the growth over time 
of cancer-related CUAs and the cost-effectiveness of new FDA approved 
interventions. METHODS: We systematically searched the Tufts Cost-
Effectiveness Analysis Registry (www.cearegistry.org) for original cancer-related 
CUAs published through 2010. In addition to overall descriptive statistics, we 
analyzed the cost-effectiveness of all FDA- approved cancer therapies from 2000 
to 2010. RESULTS: We identified 493 cancer-related CUAs from 2000-2010 (16%  
of all studies in the Registry during that time period). The number of cancer 
studies has increased dramatically; since 2006, the total has more than doubled. 
Among cancer therapies approved by the FDA from 2000 to 2010, over 50% had 
relevant cost-utility ratios. Among CUAs focused on newly-approved therapies, 
55% were sponsored by industry compared to 21% industry-sponsorship of 
studies focused on all other therapies, which includes non-drug and older  
and non-approved FDA therapies. The median reported cost-effectiveness ratio 
(US$2010) was $28,000 for all cancer studies. For therapies approved by the FDA 
from 2000 to 2010 the median ICER was $29,000. For newly-approved therapies, 
industry sponsorship was associated with a median ICER of $23,000 compared  
to $49,000 for non-industry sponsored studies (p=.01). CONCLUSIONS:  
The number of CUAs related to cancer continues to grow. Despite high costs, 
many newly-approved therapies have ratios reflecting relatively good value for 




COST-EFFECTIVENESS OF BENDAMUSTINE+RITUXIMAB VERSUS 
FLUDARABINE+RITUXIMAB IN THE TREATMENT OF RELAPSED INDOLENT  
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OBJECTIVES: Recurrent disease represents a clinical challenge in the treatment 
of indolent non-Hodgkin’s lymphoma (iNHL) and mantle cell lymphomas (MCL). 
The combination of fludarabine+rituximab (FR) is among the current treatments 
for relapsed iNHL and MCL. The objective of this study was to assess the 
economic impact of bendamustine-rituximab (BR) compared to FR in the 
treatment of relapsed iNHL and MCL in Canada. METHODS: The cost-
effectiveness of BR compared to FR in the treatment of relapsed iNHL/MCL was 
assessed over a lifetime horizon using a time-dependent Markov model. The 
Markov model comprises three health states: progression-free (PF), progressive 
disease (PD) and death. The length of each Markov cycle is one month. All 
patients start in the PF state and could move to other health states thereafter, 
according to the respective efficacy of each treatment. The model also takes into 
account the incidence of treatment-induced adverse events including grade 4 
haematological events and all grades nausea. Utility values associated with each 
health state and adverse events were used to estimate the number of QALYs 
associated with each treatment. Analyses were conducted from both a Canadian 
Ministry of Health (MoH) and a societal perspective. RESULTS: Compared with 
FR, BR is associated with ICERs of $38,821 per QALY and $45,809 per QALY, from a 
MoH and societal perspective respectively. Exhaustive sensitivity analyses 
confirm the robustness of the base-case scenario. Specifically, results of the 
probabilistic sensitivity analysis indicated that, according to a willingness to pay 
of $50,000, BR remains a cost-effective strategy in 100% and 90.2% of the 
simulations. CONCLUSIONS: This economic evaluation demonstrates that 
bendamustine in combination with rituximab is a cost-effective strategy in the 
treatment of relapsed iNHL/MCL when compared with fludarabine in 
combination with rituximab.  
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OBJECTIVES: Many breast cancer patients suffer from (severe) menopausal 
symptoms after an early onset of menopause caused by cancer treatment. The 
standard treatment for these complaints is hormone replacement therapy, 
which, however, is contraindicated for this group, as it may have tumor-
promoting effects. The aim of this study was to assess the cost-effectiveness of 
three interventions aimed at alleviating these symptoms: cognitive-behavioral 
therapy (CBT), physical exercise (PE), and the combination of both (CBT+PE). 
METHODS: A cost-effectiveness analysis was performed from a health care 
system perspective. The primary outcome was incremental health care costs 
(IHCC) per patient with a clinically relevant improvement after six months of 
treatments. The secondary outcome was incremental costs per quality-adjusted 
life years (QALYs) gained over a five-year time period. This was assessed using a 
Markov model, populated with data from a recent randomized controlled trial 
evaluating the effectiveness of CBT, PE, and CBT+PE in the clinical setting and 
additional cost data. The robustness of the results was analyzed through one-
way and probabilistic sensitivity analyses. RESULTS: IHCCs for alleviating one 
patient of the perceived symptom burden by a clinically relevant difference after 
six months of treatment were EUR€605 for CBT, EUR€1,847 for CBT+PT, and 
EUR€1,250 for PE alone, compared to the waiting list control group. CBT 
generated 0.009 additional QALYs at an additional cost of EUR€162, compared to 
the control group, leading to an Incremental Cost Utility Ratio (ICUR) of 
EUR€18,655 per QALY gained and The ICUR of CBT+PE was EUR€42,375 per QALY 
in comparison to the control group. CBT had a high probability (circa 61%) of 
being cost-effective at prevailing ceiling ratios. CONCLUSIONS: CBT is likely the 
most cost-effective of the three interventions investigated for alleviating 
treatment-induced menopausal symptoms in breast cancer patients.  
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OBJECTIVES: Non-Hodgkin’s lymphoma (NHL) is the most common lymphoma 
type, comprising approximately 90% of all malignant lymphomas, and is the 
seventh most commonly diagnosed cancer in North America. For patients with 
advanced, symptomatic indolent NHL (iNHL), rituximab is among the standard 
first-line induction therapy. For rituximab-refractory iNHL cases, alternative 
treatments are limited and comprised radioimmunotherapy treatments such as 
ibritumomab tiuxetan. The objective of this study was to assess the economic 
impact of bendamustine compared to ibritumomab tiuxetan in the treatment of 
rituximab-refractory iNHL in Canada. METHODS: A time-dependent Markov 
model with one-month cycles was constructed to assess the cost-effectiveness of 
bendamustine compared to ibritumomab tiuxetan in the treatment of rituximab-
refractory iNHL. The Markov transition model comprises three health states: 
progression-free (PF), progressive disease (PD) and death. All patients start in the 
PF state and could move to other health states thereafter, according to the 
respective efficacy of each treatment. The model also takes into account the 
incidence of treatment-induced adverse events including grade 4 haematological 
events and all grades nausea. Utility values associated with each health state 
and adverse events were used to estimate the number of QALYs associated with 
each treatment. Analyses were conducted from both a Canadian Ministry of 
Health (MoH) and a societal perspective over a lifetime horizon. RESULTS: 
Compared with ibritumomab tiuxetan, bendamustine is associated with ICERs of 
$35,490 per QALY and $42,130 per QALY, from a MoH and societal perspective 
respectively. Exhaustive sensitivity and complementary analyses confirm the 
robustness of the base-case scenario. Results of the probabilistic sensitivity 
analysis indicated that, according to a willingness to pay of $50,000, 
bendamustine remains a cost-effective strategy in 99.9% and 96.3% of the 
simulations. CONCLUSIONS: This economic evaluation demonstrates that 
